133 related articles for article (PubMed ID: 23004574)
21. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
22. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
23. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
24. Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Drygin D; Haddach M; Pierre F; Ryckman DM
J Med Chem; 2012 Oct; 55(19):8199-208. PubMed ID: 22924342
[No Abstract] [Full Text] [Related]
25. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
26. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
[TBL] [Abstract][Full Text] [Related]
27. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
28. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
29. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
30. Computational analysis of benzofuran-2-carboxlic acids as potent Pim-1 kinase inhibitors.
Wadood A; Jamal SB; Riaz M; Mir A
Pharm Biol; 2014 Sep; 52(9):1170-8. PubMed ID: 24766364
[TBL] [Abstract][Full Text] [Related]
31. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
32. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
33. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
34. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation.
Walpen T; Kalus I; Schwaller J; Peier MA; Battegay EJ; Humar R
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):24-30. PubMed ID: 23131564
[TBL] [Abstract][Full Text] [Related]
35. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
36. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
[TBL] [Abstract][Full Text] [Related]
37. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
Bamborough P; Drewry D; Harper G; Smith GK; Schneider K
J Med Chem; 2008 Dec; 51(24):7898-914. PubMed ID: 19035792
[TBL] [Abstract][Full Text] [Related]
38. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
39. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.
Zippo A; De Robertis A; Serafini R; Oliviero S
Nat Cell Biol; 2007 Aug; 9(8):932-44. PubMed ID: 17643117
[TBL] [Abstract][Full Text] [Related]
40. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]